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ABSTRACT
Existing microarray-based approaches for
screening of DNA methylation are hampered by a
number of shortcomings, such as the introduction
of bias by DNA copy-number imbalances in the test
genome and negligence of tissue-specific methyla-
tion patterns. We developed a method designated
array-based profiling of reference-independent
methylation status (aPRIMES) that allows the
detection of direct methylation status rather than
relative methylation. Array-PRIMES is based on the
differential restriction and competitive hybridiza-
tion of methylated and unmethylated DNA by
methylation-specific and methylation-sensitive
restriction enzymes, respectively. We demonstrate
the accuracy of aPRIMES in detecting the methyla-
tion status of CpG islands for different states of
methylation. Application of aPRIMES to the DNA
from desmoplastic medulloblastomas of monozy-
gotic twins showed strikingly similar methylation
profiles. Additional analysis of 18 sporadic medullo-
blastomas revealed an overall correlation between
highly methylated tumors and poor clinical outcome
and identified ZIC2 as a frequently methylated gene
in pediatric medulloblastoma.
INTRODUCTION
DNA methylation has been shown to play an essential
role in various physiological processes such as mammalian
development (1), genomic imprinting (2), X chromosome
inactivation (2) and aging (3). DNA methyltransferases
(DNMTs), three of which have been identiﬁed in
humans to date, are responsible for de novo methylation
(mainly DNMT1, DNMT3a and DNMT3b) as well
as for maintenance of methylation (mainly DNMT1).
The importance of these enzymes has been shown in
mouse models. Mice deﬁcient in any of the three DNMTs
die early in development or immediately after birth (4).
Hypomethylation of bulk genomic DNA (5,6) and
hypermethylation of CpG islands (CGIs) (7) have been
implicated in the initiation and progression of human
cancer. Deﬁned as stretches of genomic DNA 4500bp
with a GþC content  55% and observed CpG:expected
CpG dinucleotide ratio of 40.65, CGIs are most fre-
quently encountered in promoter regions or ﬁrst exons
of genes (8), and  60% of genes harbor a CGI in their
50 region (9). Hypermethylation of promoter CGIs may
lead to transcriptional repression of associated genes, e.g.
tumor-suppressor genes (TSGs). Epigenetic silencing is
well recognized as a ‘third pathway’ in Knudson’s model
of TSG inactivation in cancer, which requires inactivation
of both alleles of a gene (10,11). Moreover, as many or
even more loci can be subject to hypermethylation as
*To whom correspondence should be addressed. Tel:þ49-6221-424619; Fax: þ49-6221-424639; Email: m.macleod@dkfz.de
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.are inactivated by mutations in human cancer (11).
On the other hand, hypomethylation of promoter
sequences may reactivate the expression of silenced
oncogenes and hypomethylation of mobile genomic
elements leads to chromosomal instability, linking epige-
netic and genetic phenomena (12). The methylation status
of speciﬁc gene promoters could be linked to the
pathogenesis of various types of cancer (13), and tumor-
speciﬁc methylation changes have been established as
prognostic markers in many tumor entities (13).
Epigenetic events moved into the focus of interest of
many researchers and clinicians due to the fact that, unlike
genetic modiﬁcations such as mutations or genomic
imbalances, epigenetic changes are potentially reversible,
making them especially interesting therapeutic targets in
cancer and other diseases. Demethylating agents such as
azacytidine and some of its derivatives are under extensive
investigation for clinical application in patients with
hematological malignancies (14) as well as in solid
tumors (15). In medulloblastoma, no genome-wide
approach to study methylation patterns has been con-
ducted to date. However, several genes, such as RASSF1,
CASP8 and HIC1, were shown to be frequently hyper-
methylated in their promoter regions (16–18).
In recent years, diﬀerent techniques have been
developed for genome-wide screening of CGI methylation
in normal as well as in diseased tissues. Along with
restriction landmark genomic scanning (RLGS) (19)
and mass spectrometry (MALDI-TOF) (20) approaches,
various DNA microarray-based methods have been
established using diﬀerent microarray platforms [CGI
arrays, BAC arrays (21), oligonucleotide arrays (22)] and
diﬀerent procedures for amplicon generation. The ﬁrst
and most widely used method, diﬀerential methylation
hybridization (DMH), was introduced by Huang and
coworkers in 1999 (23). DMH is used to determine the
methylation of CGI sequences in a test sample relative to
a control sample. Test and control DNA are digested with
one or several methylation-sensitive enzyme(s) and only
the methylated, and hence uncut, DNA is ampliﬁed by
linker-mediated PCR. The PCR products are diﬀerentially
labeled, and hybridized to a CGI microarray. DMH
has been used to study aberrant methylation patterns in
various tumor entities and cell lines (24,25). DMH typi-
cally compares tumor tissue and unrelated control tissue,
as the cell type of tumor origin is often unknown or the
cell population is too small to obtain suﬃcient amounts
of control DNA. Tissue-speciﬁc methylation patterns
of unrelated control tissues, however, will likely result in
numerousfalse-positiveandfalse-negativeresults.Further-
more, DNA copy-number imbalances severely bias the
readout of this method, since regions of copy-number
gains and losses erroneously appear as hypermethylated
and hypomethylated, respectively, if methylation-sensitive
restriction is incomplete.
A variation of the DMH technique proposed by Adrien
et al. (26) uses isoschizomeres to perform a methylation-
sensitive and methylation-insensitive digestion at the
same restriction site. Although this method theoretically
overcomes problems of genomic imbalances and tissue-
speciﬁc methylation patterns, the approach has a principal
weakness in that unmethylated sequences will not give
a ﬂuorescence signal at all since they will be cut by
both enzymes and will therefore not be ampliﬁed in the
following PCR.
More recently, methylated DNA immunoprecipitation
(MeDIP) and methylated-CGI island recovery assay-
assisted microarray analysis (MIRA) were introduced as
alternative methods for the enrichment of methylated
DNA (27,28). Although being an elegant alternative for
some applications, the major disadvantage of the MeDIP
assay is the large amount of template DNA required
(minimum 4mg), which is often not feasible for clinical
applications. If an ampliﬁcation step is included, PCR bias
is introduced due to the fact that ‘precipitate’ (enriched
in methylated CGIs) and ‘cleared input’ (genomic DNA
not enriched for CGIs) signiﬁcantly diﬀer in their GC
content and thereby in their performance during PCR
ampliﬁcation.
McrBC, the methylation-speciﬁc enzyme used for
array-based proﬁling of reference-independent meth-
ylation status (aPRIMES), has initially been used in
methylation studies to remove methylated sequences from
genomic DNA and to map methylated sites, e.g. on
metaphase chromosomes (29–31). Later it has also been
incorporated in a micorarray-based methylation proﬁling
approach (32).
To overcome some of the limitations of established
methods, we developed a novel technique designated
aPRIMES for genome-wide detection of CGI methylation
status, which is independent of a control tissue.
MATERIALS AND METHODS
Tumor material and patientcharacteristics
Tumor samples were collected by W. Scheurlen at the
Department of Pediatric Oncology, Wuerzburg University
Hospital (Wuerzburg, Germany) and Department of
Pediatric Oncology, Mannheim University Hospital
(Mannheim, Germany), between 1994 and 2002. All
diagnoses were conﬁrmed by histological assessment
of specimens obtained at neurosurgery by at least two
neuropathologists according to the criteria of the World
Health Organization (WHO) classiﬁcation. Approval to
link histological data to clinical data was obtained by the
Institutional Review Board. This procedure is according
to the oﬃcial statement of the National Ethics Council
of the Federal Government of Germany (March 2004).
Staging procedures included MRI before and immediately
after neurosurgery. Metastatic disease was detected by
craniospinal imaging and lumbar puncture. Patients were
treated according to German standard therapy protocols
of the HIT study group. Genomic DNA from normal
cerebellum (pool of ﬁve donors, age 25–33 years) was
purchased from Biocat (Heidelberg, Germany).
Nucleic acid isolation
Extraction of high molecular weight DNA and RNA from
frozen medulloblastoma samples was carried out by ultra-
centrifugation in cesium chloride as previously described
(46). Total RNA quality and concentration was controlled
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CGI library and probepreparation
A human library consisting of 10560 bacterial clones
harboring DNA sequences enriched for CGIs was
purchased from the UK HGMP (http://www.hgmp.mrc.
ac.uk/). This clone set is part of the original CGI library
which was generated by Cross et al. (33). To amplify CGI
sequences, library aliquots were grown in 1ml LB media
plus ampicillin (50mg/ml) overnight at 378C. PCR was
performed in a 96-well format (MWG, Ebersberg,
Germany) using 2ml of bacterial culture supplemented
with 10% DMSO, 180mM dNTPs, 150nM of each
primer, 1.8mM MgCl2 and 2U Eurotaq Polymerase
(Biocat, Heidelberg, Germany). Thirty-ﬁve ampliﬁcation
cycles were performed including denaturing at 948C
for 30s, annealing at 588C for 30s and elongation
at 728C for 60s. Primers used for ampliﬁcation were
pGEM-for (50-GGCCGCGGGATATCACTA-30) and
pGEM-rev (50CTCAAGCTATG CATCCAACG-30). All
CGI sequences were reampliﬁed by using 5ml of product
of the ﬁrst PCR as a template for a second PCR under
identical conditions. The second PCR resulted in more
homogenous product quantities for microarray printing.
CGI microarrayproduction
For microarray printing, 30 ml of PCR products was
dried in a vacuum centrifuge and resuspended in 12ml
spotting buﬀer (3 SSC, 1.5M betaine). PCR products
were printed onto amino-silane-coated Corning
TM Gaps
II slides (Corning, Acton, USA) in triplicates using a
printing robot (OmniGrid, GeneMachines, San Carlos,
USA) and 48 (4 12 conﬁguration) Telechem SMP3
pins (Telechem International, Sunnyvale, USA) at 208C
and 40% humidity. After printing, slides were UV
cross-linked, baked for 2h at 808C, and UV cross-linked
again.
aPRIMES
Here, 500ng genomic DNA was restricted to completion
with 10U MseI for 3h in a ﬁnal volume of 10ml in the
buﬀer provided by the supplier (New England Biolabs,
Beverly, USA). Heat inactivation was carried out at
658C for 20min. MseI fragments were then subjected to
linker-mediated PCR as essentially described by Klein
and coworkers (47). Brieﬂy, 1ml each of 100mM stock
solution (MWG, Ebersberg, Germany) ddMse11 (50-TAA
CTGACAG-30) and Lib1 (50-AGTGGGATTCCTGCTG
TCAGT-30) were annealed in 1ml One-Phor-All-Buﬀer
and 3ml ddH2O. Annealing was started at a temperature
of 658C and was shifted down to 158C with a ramp of
18C/min. At 158C, 10ml MseI fragments, 2ml of ATP
(10mM) and 2ml T4-DNA-Ligase (10U; Roche,
Grenzach-Wyhlen, Germany) were added, and primers
and DNA fragments were ligated overnight.
Half of the resulting ligated MseI fragments were
digested with the restriction enzyme McrBC (New
England Biolabs, Beverly, MA, USA) for 8h following
the conditions recommended by the supplier. The other
half of the MseI fragments was digested with the two
methylation-sensitive endonucleases HpaII (New England
Biolabs; recognition site CCGG, 3h, 378C) and BstUI
(New England Biolabs; recognition site CGCG, 3h,
608C) according to the recommendations of the supplier.
Digested DNA fragments were then treated with 1ml
Proteinase K (Invitrogen, Karlsruhe, Germany) for 1h at
378C with subsequent heat inactivation at 808C for 10min.
For the following ampliﬁcation step, 10ml consisting
of 2ml1 0 Expand Long Template buﬀer 1 (Boehringer,
Mannheim, Germany), 1ml dNTPs (10mM), 1ml Lib1
primer (50-TAACTAGCATGC-30), 1ml expand long tem-
plate DNA polymerase mixture (Boehringer, Mannheim,
Germany) and 5ml ddH2O were added to 20ml reaction
volume. A MWG thermocycler was programmed to 728C
for 3min, followed by 20 cycle loops at 948C (30s), 628C
(30s) and 728C (90s). Final elongation was carried
out at 728C for 10min. PCR products were recovered
by ethanol precipitation. DNA was eluted in 30ml
0.1 TE, pH 8.
Labelingand hybridization to microarrays
Labeling, hybridization and washing procedures were
adapted from a previously published protocol (48).
Brieﬂy, 13ml of both the McrBC-digested and the
HpaII/BstuI-digested samples of each tumor were
diﬀerentially labeled with Cy3- or Cy5-conjugated dCTP
by use of a BioPrime DNA Labeling Kit (Invitrogen,
Karlsruhe, Germany). Here, 75ml(  10mg) each of McrBc
and Hpa/BstUI samples were combined with 150mg
human Cot-1 DNA (Roche Diagnostics, Mannheim,
Germany) to block repetitive sequences. Unincorporated
nucleotides, random primers and dyes were removed by
ethanol precipitation. Precipitated DNA was resuspended
in 135ml Ultrahyb
TM hybridization buﬀer (Ambion,
Bad Soden, Germany). Denaturation of samples was
performed at 758C for 10min, followed by re-annealing
at 378C for 30min. Hybridization was carried out in a
GeneTAC Hybridization Station (Genomic Solutions,
Oberhaching, Germany) for 40h at 378C. Slides were
washed with 2 SSC/0.05% Tween-20at 378C for 1 cycle,
2 SSC/0.05% Tween-20at 448C for 2 cycles, 50%
formamide/2 SSC/0.1% Tween-20at 448C for 3 cycles,
2 SSC/0.05% Tween-20at 448C for 2 cycles, and ﬁnally
1 PBS/0.05% Tween-20at 258C for 2 cycles. Slides were
dried by centrifugation at 216g for 3min in a clinical
centrifuge.
Image andmicroarray dataanalysis
Arrays were scanned with an Agilent DNA microarray
scanner (Agilent Technologies, Palo Alto, USA) and
images analyzed using GenePix Pro 6.0 software (Axon
Instruments, Burlingame, USA). Fluorescence intensities
of all spots were ﬁltered consistently (intensity/
local background 41.1; mean/median intensity 50.25;
coeﬃcient of variation of log2-ratios between replicated
spots40.3 if range of log2-ratios of replicated spots40.2).
Global normalization was performed in three steps. First,
we applied a normalization for print-order eﬀects using the
loess smoother, as described in Smyth et al. (49). In
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tonormalizethelog2-ratios foreacharrayseparatelybythe
use of print-tip loess (49). Third, to normalize between
arrays, quantile normalization was performed as described
by Yang and Thorne (50). Normalization was carried out
using zero weights for previously ﬁltered spots. The data
sets discussed in this publication have been deposited in
NCBIs Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/) and will be accessible through GEO Series
accessionnumberGSE4857afterpublicationofthisarticle.
Internal controls
Spike CGIs from rice were used as positive controls for
methylation. Ten rice CGIs were PCR ampliﬁed and
printed on the microarray. Sample DNAs for aPRIMES
were spiked with  10pg of each in vitro methylated rice
CGI. Mitochondrial CGI clones present in the original
library were used as controls for unmethylated and
allelically/partially methylated CGIs.
Sequenceinformation of candidateCGIs
Sequence information for CGI clones was obtained from a
publicly available database at http://data.microarrays.ca/
cpg/index.htm. Chromosomal annotation of sequences is
based on the University of California at Santa Cruz
(UCSC) genome database (Freeze, May 2004). Here, 150
clones from the CGI library, including the two clones
representing the ZIC2 promoter region, were sequenced
with the same primers as used for ampliﬁcation.
Bisulfite conversion andpyrosequencing
Here, 500ng of patient-sample-derived DNA was bisulﬁte-
converted according to standard protocols. The modiﬁed
DNA was subjected to PCR ampliﬁcation and subsequent
pyrosequencing. Primer sequences for the PCR ampliﬁca-
tion were F_102212_zic2: 50-GGGATTTTTTGGTTTTT
GAAGA-30 and R_102212_zic2: 50- Biotin-AACCACA
AAACCCACAACTATC-30. Ampliﬁcation was carried
out after an initial denaturation step (948C, 3min) for 50
cycles of 30s at 948C, 30s at 548C and 45s at 728C in a ﬁnal
volume of 50ml. Final extension was performed for 5min
at 728C. In vitro methylated DNA from peripheral blood
mononuclear cells of healthy donors was used as a positive
control for the methylated status (IVM). In vitro methyla-
tion was carried out using SssI in vitro methylase (New
England Biolabs, Beverly, USA) for 4h according to the
manufacturer’s instructions.
Here, 30ml of PCR product was immobilized to 3ml
Streptavidin Sepharose
TM HP beads (GE Healthcare,
formerly Amersham Biosciences) followed by annealing
to 4 pmol sequencing primer for 20 at 808C. Sequencing
primers were S1_102212_zic2 (50-GTTTTTGAAGATAA
TTTTAAT-30) for CpG 1-5 and S2_102212_zic2 (50-GGT
TTTGAGTTGGATT) for CpG 6-12. The analysis criteria
were those speciﬁed by the manufacturer’s settings. CpG
analysis were done with Pyro Q-CpG software.
QRT-PCR
To correlate the methylation status of ZIC2 with mRNA
expression, 5mg of total RNA from tumor samples
and normal human cerebellum (pool of 24 individuals,
aged 16–70; BD Biosciences, San Jose, USA) as a reference
was used as a template for reverse transcription with
the SuperscriptII ﬁrst-strand synthesis kit (Invitrogen,
Karlsruhe, Germany). Each cDNA sample was analyzed
in triplicate using ABI PRISM 7700 (Applied Biosystems,
Foster City, USA) with Absolute SYBR Green ROX Mix
(ABgene, Epsom, UK) according to the manufacturer’s
instructions. Two endogenous housekeeping genes (PGK1,
LMNB1) were used for internal normalization. All primers
were tested to exclude ampliﬁcation from genomic DNA.
Quantiﬁcation of the transcript of interest relative to
the housekeeping genes was calculated according to a
previously published algorithm (51). Oligonucleotide
sequences for ZIC2 were for 50-TCCGAGAACCTCAAG
ATCC and rev 50-TAGGGCTTATCGGAGGTG.
RESULTS
Methylation analysis using aPRIMES
Array-PRIMES compares two diﬀerentially restricted
aliquots from the same genome of interest by competitive
hybridization to a CGI array. By performing a test-
versus-test rather than test-versus-control hybridization,
inﬂuences of tissue-speciﬁc methylation patterns in the
control DNA as well as of DNA copy-number imbalances
that might be present in the test, but not in the control
genome, are avoided. Due to ampliﬁcation of whole
genomic DNA in both parts of the sample, no PCR bias
is introduced. The ﬂowchart of our newly developed
protocol is depicted in Figure 1a. Brieﬂy, genomic (tumor)
DNA is digested with MseI and ligated to adapter
primers. Subsequently, one-half of the sample is digested
with the methylation-sensitive restriction enzymes HpaII
and BstUI to cut unmethylated CGIs, and the remaining
half is digested with the methylation-speciﬁc enzyme
McrBC to cut methylated CGIs. Since the probability
of a McrBC recognition sequence (50 ...Pu
mC[N40–3000]
Pu
mC...30) to be present within a CGI is close to 100%,
and the probability for either a HpaII or BstUI site was
found to be  90% in the 150 clones that we have sequen-
ced, the vast majority of clones on the CGI microarray
are potentially informative. Restricted samples are then
subjected to 20 cycles of linker-mediated PCR, diﬀeren-
tially labeled with ﬂuorescent dyes, and competitively
hybridized to a CGI microarray. The microarray used
for this study consists of 10560 sequences enriched for
CGIs as obtained by isolation over a MeCP2 (methyl-
CpG-binding protein 2) aﬃnity column by Cross and
coworkers (33), 595 PCR products of interest representing
regions of frequent genomic losses in medulloblastoma
that might harbor yet-unidentiﬁed TSGs, and 10 CGIs
from rice that can be used to spike the test DNA.
Rice DNA was chosen to rule out cross-hybridization with
human CpG-rich sequences.
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Figure 1. Flowchart for the array-PRIMES procedure and performance of the method. (a) Flowchart and overview of expected results for
methylated and unmethylated CGIs. (b and c) Performance of aPRIMES on CGI microarrays. All clones are spotted in triplicate. A representative
block is shown for (b) normal cerebellum (pool of ﬁve unaﬀected donors) and (c) in vitro methylated tumor DNA. Red spots indicate methylated
clones, green spots indicate unmethylated clones, yellow spots indicate mixed or allelic methylation, and can also be caused by a lack of appropriate
restriction sites. (d) Quantiﬁcation of methylation of spike CGIs using diﬀerent proportions of methylated and unmethylated spike DNA spiked into
genomic DNA of one tumor. Spots indicate the normalized ratios of all eight spike clones used in each of ﬁve experiments; short horizontal lines
represent the median ratio of eight clones. The regression line is based on the medians depicted in the diagram. (e) Performance of internal control
clones. Median values and median absolute deviations from the median (MADs) of 20 unselected aPRIMES experiments (upper part) and spot data
from one representative hybridization (lower part) are shown. Methylated clones are highlighted in red and are expected to result in positive ratios;
mitochondrial clones with methylation-sensitive restriction sites are highlighted in green and are to have negative ratios. Mitochondrial clones
without methylation-sensitive restriction sites are depicted in yellow and are to be balanced.
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CGI methylation in 20 pediatric medulloblastomas and
normal cerebellum (pool of ﬁve unaﬀected donors, age
25–33 years). A representative section of a CGI micro-
array hybridized with cerebellum pool DNA is shown in
Figure 1b. Most clones indicate an unmethylated state
(green spots), some clones are clearly methylated (red),
whereas most of the remaining spots show a faint or
even absent ﬂuorescence signal. This result is obtained
whenever restriction sites for methylation-sensitive
and methylation-speciﬁc enzymes are both present in
each copy of the respective DNA stretch. In a typical
aPRIMES experiment,  20% of all clones are ﬁltered out
due to this reason during data processing. Yellow spots
are not as frequent and represent a balanced status.
This can be caused by various scenarios: allelic meth-
ylation, diﬀerential methylation in subsets of tumor cells
or unmethylated clones lacking a methylation-sensitive
restriction site (HpaII or BstUI). In vitro methylated
tumor DNA was used as a positive control to detect the
proportion of clones that can potentially be methylated
(Figure 1c). The vast majority of clones (490%) indicate
a methylated status in these experiments. The reproduci-
bility of the method is excellent. Spearman
correlation coeﬃcients (r) for the correlation of
normalized results are typically 40.90 (Supplementary
Figure 1 online).
To verify that aPRIMES detects the direct methylation
status of a given CGI, we performed ﬁve experiments
with DNA from the same tumor and spiked diﬀerent
proportions of methylated:unmethylated DNA (0:1, 1:3,
1:1, 3:1 and 1:0) from eight rice CGIs into the tumor
DNA. Figure 1d illustrates that aPRIMES accurately
detects quantitative diﬀerences in the percentage of
methylated DNA.
For internal validation of each experiment, we used
a set of 24 control clones reﬂecting the diﬀerent states
of methylation: 14 clones derived from mitochondrial
DNA that were part of the clone library and 10 CGI
clones from rice (Figure 1e). Mitochondrial DNA is
known to be unmethylated in vivo (34). Therefore,
mitochondrial CGIs represent the unmethylated state
(appearing green on the microarray) when containing a
methylation-sensitive restriction site (clones CGI-091F5
to CGI-117A3), or the balanced state (yellow) if no
methylation-sensitive restriction site is present (CGI-
001F12 to CGI-094F12). In the latter case, none of the
applied enzymes is eﬀective, and DNA is ampliﬁed in
both, the methylation-sensitive and methylation-speciﬁc
restriction aliquots. As a control for the methylated
state, 10 CGIs from rice represented on the CGI array
(Spike-1 to Spike-10) were in vitro methylated and
spiked into the tumor DNA prior to enzymatic
restriction. The median ratio over all 20 aPRIMES
analyses of medulloblastomas and the typical appear-
ance on the hybridized CGI array are shown for each
of the 24 control clones (Figure 1e). In all three
control groups, the correct methylation status was
indicated by all clones, including those with low
signal intensities.
Global CGImethylation in medulloblastomas
from monozygotic twins andsporadic cases
Two of the analyzed medulloblastomas were derived
from monozygotic twins presenting with desmoplastic
medulloblastoma at three years of age. Analysis of DNA
copy-number by array-CGH (median resolution  0.4kb)
showed that none of the tumors carried chromosomal
aberrations (data not shown). CGI methylation analysis
by aPRIMES, however, clearly showed aberrant meth-
ylation of the tumor genomes compared to normal
cerebellum, indicating that aberrant DNA methylation
is involved in the pathogenesis of the twins’ tumors
(Figure 2a). Interestingly, the epigenomes of the tumors
were strikingly similar to one another (Figure 2b), but
quite diﬀerent from that of an unrelated sporadic tumor
(Figure 2c), suggesting that the twin’s tumors share a
unique epigenetic pathomechanism.
Comparison of methylation patterns between tumors
revealed considerable variability in the overall degree
of CGI methylation. For example, many more clones were
methylated in medulloblastoma M5 than M1 (Figure 2c,
upper left quadrant). Representative sections of the arrays
of both patients are given in Figure 2d and e. Examples for
clones methylated in M5 and unmethylated in M1 are
highlighted with white circles. These diﬀerences in global
methylation prompted us to compare the percentage of
highly methylated clones in a set of 20 medulloblastoma
samples. For this purpose, we determined the median
absolute deviation from the median (MAD) as a robust
estimate of the true standard deviation over all clones
present in at least 50% of experiments after consistent
ﬁltering for each sample. Clones with log2-ratios of more
than two MADs above the median were assumed to be
highly methylated. When applying this threshold to the
validation experiment shown in Figure 1d, only two of the
spike CGIs with a methylated:unmethylated proportion of
3:1 will be regarded as highly methylated, whereas all fully
methylated spike CGIs will. Based on this conservative
threshold, we grouped the 20 patients (including the twins)
into two equally large groups according to the percentage
of highly methylated clones. Concerning histological
subtypes, both groups are comparable: The low methy-
lator group contains three patients with desmoplastic
tumors (one in the high methylator group) and one patient
with anaplastic tumor (none in the high methylator
group); the remaining cases are classic medulloblastomas.
The groups are also comparable with regard to patient age
(mean 6.1 versus 6.7 years), gender (ﬁve male versus ﬁve
female patients in both groups) and therapy regimen
(three versus two patients were 2 years or younger and
were therefore not subjected to radiotherapy). Patients in
the low methylator group have 8.9% or less of highly
methylated clones (range: 6.2–8.9%, 10 patients). The
remaining 10 patients were grouped into a high methy-
lator group having 9% or more highly methylated clones
(range 9–11.2%). Interestingly, patients in the low
methylator group had a better prognosis than patients in
the high methylator group in this series. The median
overall survival was 52 and 84 months in the low and high
methylator groups, respectively. Whereas only 1/10
e51 Nucleic Acids Research, 2007, Vol. 35, No. 7 PAGE6 OF11patients died in the ﬁrst group, 5/10 patients died in the
high methylator group after a median follow-up of 79
months. The Kaplan–Meier plot (Figure 2f) shows the
estimated survival probability of the two groups (log-
rank-test: P¼0.05). Furthermore, the global methylation
status is not associated with the frequency of copy-number
alterations in the tumor genome. For example, the tumor
displaying the highest percentage of methylated clones
shows a balanced tumor genome as assessed by array-
based comparative genomic hybridization (data not
shown).
ZIC2is differentially methylated andepigenetically
silenced inpediatric medulloblastoma
For the identiﬁcation of candidate clones, highly repetitive
sequences (repeat content 450% according to the
UNH database at www.data.microarrays.ca/cpg/) were
excluded. We next sorted individual clones according to
their MAD to screen for diﬀerentially methylated clones
within the series of medulloblastomas. Two of the most
diﬀerentially methylated clones were CGI-027A11 and
CGI-028A11 representing the CGI of the zinc-ﬁnger
protein of the cerebellum family member 2 (ZIC2) gene.
Clone identities were conﬁrmed by DNA sequencing (data
not shown). The predicted CGI within the MseI fragment
is depicted in Figure 3a. The methylation status of ZIC2
in 20 medulloblastomas as well as in appropriate positive
and negative controls was assessed by pyrosequencing
of the region indicated in Figure 3a covering 12 individual
CpG sites (Figure 3b, grey bars and Supplementary
Figure 2). The percentages indicated in Figure 3b
reﬂect the median methylation of all investigated CpG
dinucleotides for each sample. Conﬁrming the results
obtained by aPRIMES, the signal ratios from the
microarray experiments show an excellent correlation
with the pyrosequencing results (Spearman correlation
¼0.89). Diﬀerences between the readout obtained by
pyrosequencing and aPRIMES (mainly tumors M6, M12,
M17 and M18) may well be explained by additional
methylation sites outside the pyrosequencing region.
To further assess the functional impact of this methylation
event, we measured mRNA expression in tumors,
of which RNA was available using quantitative real-
time PCR. Notably, we found silencing of mRNA
expression in most medulloblastoma samples when
normalized to a pool of normal cerebellum in two
independent experiments, corroborating the results of
our methylation analyses (Figure 3c). The downregulation
of mRNA expression in tumor M4 cannot be explained by
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Figure 2. Application of aPRIMES in pediatric medulloblastoma identifying groups with low and high methylation. (a–c) Scatter plots representing
the correlation of methylation patterns of monozygotic twins (patients M1 and M10) with simultaneous desmoplastic medulloblastoma, a case of
sporadic classic medulloblastoma (M5), and normal cerebellum. (a) twin one (patient M1) in comparison with normal cerebellum (pool of ﬁve
unaﬀected donors), (b) twin 1 versus twin 2 (patient M10) and (c) twin one compared with a sporadic classic medulloblastoma (patient M5).
Spearman-correlation coeﬃcients (r) are given for each plot. Representative microarray sections of (d) patient M1 (low methylator group) and (e)
patient M5 (high methylator group). Examples for diﬀerentially methylated clones are highlighted with white circles. (f) Kaplan–Meier plot of
estimated survival time distribution with corresponding log-rank test. For survival analysis, patients were grouped into low and high methylator
groups according to the percentage of highly methylated clones.
PAGE 7 OF 11 Nucleic Acids Research, 2007, Vol. 35, No. 7 e51Figure 3. CGI methylation and mRNA expression of ZIC2 in pediatric medulloblastoma. (a) Schematic presentation of the predicted ZIC2 CpG
island in the 5’ UTR of the gene (chr13: 99428130-99428406) delineated according to the criteria by Gardiner-Garden and Frommer (52). MseI-sites
ﬂanking the ends of the CGI clone are shown together with their position in relation to the transcription start site. Pyrosequencing was performed for
the indicated region. (b) Comparison between pyrosequencing results (grey bars) and aPRIMES results (black bars). For comparison, aPRIMES
ratios were linearized and are given in relation to the linear ratio of tumor M3 that displayed the highest ratio among all aPRIMES samples, and was
therefore set to 100%. For the pyrosequencing data, a median over all 12 investigated individual CpG sites was calculated. The right panel illustrates
non-normalized spot-data after performance of aRPIMES. Triplicate spots for both ZIC2 clones, namely CGI-027A11 and CGI-028A11 are indi-
cated Fem. (male) pool¼DNA derived from the peripheral blood mononuclear cells (PBMCs) of 10 healthy donors below age 35. Cb pool¼pool
of cerebellum DNA from ﬁve unaﬀected donors, age 25–33 years. M1–M20: pediatric medulloblastoma samples. For medulloblastoma M8 no chip
data are available. (c) mRNA abundance of ZIC2 was assessed by quantitative real-time PCR and normalized to the expression of ZIC2 in a
cerebellum mRNA pool of 24 unaﬀected individuals. Medians and MADs of two independent experiments are shown. ZIC2 was downregulated to
diﬀerent degrees in all tested medulloblastomas, most profoundly in tumor M3 that displayed the highest methylation of the CGI.
e51 Nucleic Acids Research, 2007, Vol. 35, No. 7 PAGE8 OF11CGI methylation, and may be caused by other mechan-
isms of transcriptional regulation.
DISCUSSION
This study demonstrates that aPRIMES allows for
genome-wide detection of the direct methylation status
of individual DNA fragments with high accuracy and
reproducibility. Major limitations of established methods
(21,23) are overcome by comparative hybridization
of diﬀerentially restricted fractions of one test genome
making the procedure independent of a control tissue.
In contrast to other approaches including those based
on immunoprecipitation of methylated DNA (22,27,32),
aPRIMES can distinguish between unmethylated,
partially or allelically methylated, and fully methylated
clones. Furthermore, PCR bias is avoided due to ampli-
ﬁcation of total genomic DNA in both samples rather
than GC enriched versus total genomic DNA as required
for MeDip in clinical applications (27). In contrast to the
method proposed by Nouzova et al. (32), which was the
ﬁrst microarray-based method to be independent of
a common reference, aPRIMES data can be normalized
by commonly used algorithms (loess, vsn) because values
display a symmetric distribution around the balanced
state. Equal distribution of unmethylated and methylated
sequences may increase sensitivity to detect diﬀeren-
tial methylation. In addition, aPRIMES can distin-
guish partial and full methylation. Recently, another
microarray-based method for global methylation proﬁling
was developed, termed microarray-based methylation
assessment of single samples (MMASS) (35). This
method is comparable to aPRIMES in that it makes use
of diﬀerential restriction of the test genome. In contrast
to Ibrahim et al. (35) aPRIMES allows the quantiﬁcation
of methylation signals and between-chip normalization
by use of 24 internal control fragments representing
the diﬀerent states of methylation.
We applied aPRIMES to a series of 20 pediatric medul-
loblastomas including tumors from 3-year-old twins with
simultaneous desmoplastic medulloblastoma. Previously,
it was found that diﬀerences in the epigenomes of mono-
zygotic twins are mostly acquired with aging (36). To our
knowledge, this is the ﬁrst report on the similarity of
tumor epigenomes in monozygotic twins presenting with
a tumor of the same entity. While no gross genomic
imbalances could be detected, diﬀerences between the
methylation patterns of the twins and normal cerebellum
are demonstrated, indicating that aberrant methylation is
involved in the pathogenesis of the tumors. These results
suggest a shared epigenetic pathogenesis of the tumors.
Analysis of the methylation proﬁles of 20 pediatric
medulloblastomas revealed large diﬀerences in the propor-
tion of highly methylated CGIs. Therefore, we grouped
the patients into two equally large groups according to the
proportion of methylated clones and found that patients
in the high methylator group had a worse prognosis.
Obviously, this result has to be validated prospectively in
a larger series of tumors. However, the fact that grouping
is independent of the number of genomic imbalances,
histological subtype, age, gender and treatment regimen
makes this result a very promising basis for further
exploration. Notably, the continuous distribution of
methylation frequency obtained in this study using
unselected clones, argues against the existence of a CGI
methylator phenotype (CIMP) in medulloblastoma.
CIMP is characterized by a high degree of concordant
CGI methylation in a subset of tumors of a certain entity
and was ﬁrst described by Toyota et al. (37) as a distinct
pathway for colorectal carcinogenesis. CIMP suggests
that there should be two clearly disparate groups of
methylation frequency in a given tumor cohort, which is
not the case in the cohort analyzed here. It is important to
note, however, that the concept of CIMP is entirely based
on studies with relatively small sets of pre-selected CGI
clones. Therefore, it will be of great interest to carry out
genome-wide methylation studies with unselected clones in
larger tumor series.
Based on robust statistical analysis, two clones repre-
senting the ZIC2 CGI were among the most diﬀerentially
methylated clones within the investigated series of
pediatric medulloblastomas. Diﬀerential methylation
was validated by methylation-speciﬁc PCR, and marked
silencing of mRNA expression upon CGI methylation was
demonstrated by use of quantitative real-time PCR. ZIC2
is an interesting candidate gene in medulloblastoma for
several reasons. ZIC2 belongs to a family of ﬁve ZIC
genes that encode zinc-ﬁnger transcription factors, each of
which is composed of ﬁve Cys2His2 zinc-ﬁnger domains.
In mice, the ZIC genes were shown to be essential
for a wide variety of developmental processes, such as
central nervous system, muscle and skeletal development,
and the embryonal establishment of left–right asymmetry
(38). In humans, heterozygous deletions or mutations
in the ZIC2 gene, along with mutations in the Sonic
Hedgehog (SHH) gene and others, are found in subsets
of patients with holoprosencephaly (HPE), a congenital
malformation of the forebrain with a very diverse
phenotypic spectrum, including non-separation of the
two hemispheres and facial dysmorphisms (39). In
medulloblastoma, expression of ZIC genes was identiﬁed
as an indicator that cerebellar granule cells might be
the cells of origin for this tumor entity (40). Recently,
it has been shown that the neuronal cell-type-speciﬁc
promoter of the a CaM kinase II (CamKII) gene is
activated by ZIC2 (41). CaMKII in turn was shown to be
responsible for the phosphorylation and inactivation
of the proto-oncogene ETS1, and to antagonize wnt/
b-catenin signaling either by direct phosphorylation and
inactivation of b-catenin or by blocking TCF/LEF via
TAK1/NLK (42,43). In addition, ZIC proteins interact
with gli proteins, which function as downstream eﬀectors
of the SHH pathway. Interestingly, the expression of
ZIC family proteins grossly overlaps with expression of
the repressing Gli3 in neural tube development (44).
The genomic locus of ZIC2at chromosomal band 13q32 is
frequently lost in pediatric medulloblastoma as assessed
by array-CGH (19/102 cases; Mendrzyk et al. (45) and
data not shown). Given the frequent downregulation
of ZIC2 in medulloblastoma by aberrant methylation of
its promoter and the proposed functions of the ZIC2
PAGE 9 OF 11 Nucleic Acids Research, 2007, Vol. 35, No. 7 e51protein, our ﬁndings suggest an important role for ZIC2
in the pathogenesis of pediatric medulloblastoma.
In summary, aPRIMES will be useful as a screening
tool to identify genes regulated by DNA methylation, such
as in epigenetic reprogramming during embryogenesis,
tissue-speciﬁc gene expression, imprinting and diﬀerential
gene expression in cancer and other diseases.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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